Showing 1 - 7 results of 7 for search 'N.H. Hendrikse', query time: 0.02s Refine Results
  1. 1
    Quantification of [18F]afatinib using PET/CT in NSCLC patients: a feasibility study

    Quantification of [18F]afatinib using PET/CT in NSCLC patients: a feasibility study by E. A. van de Stadt, M. Yaqub, A. A. Lammertsma, A. J. Poot, P. R. Schober, R. C. Schuit, E. F. Smit, I. Bahce, N. H. Hendrikse

    Published 2020-08-01
    Get full text
    Article
  2. 2
    Standardized uptake values are adequate measures of [18F]DCFPyL PSMA PET/CT uptake in patients with low prostate cancer disease burden

    Standardized uptake values are adequate measures of [18F]DCFPyL PSMA PET/CT uptake in patients with low prostate cancer disease burden by Y.J.L. Bodar, B.P.F. Koene, B.H.E. Jansen, M.C.F. Cysouw, D. Meijer, N.H. Hendrikse, A.N. Vis, R. Boellaard, D.E. Oprea-Lager

    Published 2020-11-01
    Get full text
    Article
  3. 3
    Physiologically Based Pharmacokinetic (PBPK) Modeling to Predict PET Image Quality of Three Generations EGFR TKI in Advanced-Stage NSCLC Patients

    Physiologically Based Pharmacokinetic (PBPK) Modeling to Predict PET Image Quality of Three Generations EGFR TKI in Advanced-Stage NSCLC Patients by I. H. Bartelink, E. A. van de Stadt, A. F. Leeuwerik, V. L. J. L. Thijssen, J. R. I. Hupsel, J. F. van den Nieuwendijk, I. Bahce, M. Yaqub, N. H. Hendrikse

    Published 2022-06-01
    Get full text
    Article
  4. 4
    Determining the diagnostic value of PSMA-PET/CT imaging in patients with persistent high prostate specific antigen levels and negative prostate biopsies. The SESAME-study

    Determining the diagnostic value of PSMA-PET/CT imaging in patients with persistent high prostate specific antigen levels and negative prostate biopsies. The SESAME-study by Y.J.L. Bodar, B.P.F. Koene, D. Meijer, P.J. Van Leeuwen, J.A. Nieuwenhuijzen, R.J.A. Van Moorselaar, N.H. Hendrikse, D.E. Oprea-Lager, A.N. Vis

    Published 2020-11-01
    Get full text
    Article
  5. 5
    Biochemical persistence of prostate-specific antigen after robot-assisted laparoscopic radical prostatectomy: Tumor localizations using PSMA PET/CT imaging

    Biochemical persistence of prostate-specific antigen after robot-assisted laparoscopic radical prostatectomy: Tumor localizations using PSMA PET/CT imaging by D. Meijer, M.L. Donswijk, Y.J.L. Bodar, P.J. Van Leeuwen, H.G. Van Der Poel, W.V. Vogel, J.A. Nieuwenhuijzen, N.H. Hendrikse, D.E. Oprea-Lager, A.N. Vis

    Published 2020-11-01
    Get full text
    Article
  6. 6
    Detection of intraprostatic tumor localisation with 18-Fluorine Prostate-Specific Membrane Antigen (PSMA) PET/CT compared to radical prostatectomy specimens: Is PSMA-targeted biopsy feasible? the DeTeCT trial

    Detection of intraprostatic tumor localisation with 18-Fluorine Prostate-Specific Membrane Antigen (PSMA) PET/CT compared to radical prostatectomy specimens: Is PSMA-targeted biops... by Y.J.L. Bodar, B.H.E. Jansen, P.J. Van Der Voorn, G.J.C. Zwezerijnen, J.A. Nieuwenhuijzen, N.H. Hendrikse, R.J.A. Van Moorselaar, D.E. Oprea-Lager, A.N. Vis

    Published 2020-07-01
    Get full text
    Article
  7. 7
    Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer

    Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer by A. N. Niemeijer, D. Leung, M. C. Huisman, I. Bahce, O. S. Hoekstra, G. A. M. S. van Dongen, R. Boellaard, S. Du, W. Hayes, R. Smith, A. D. Windhorst, N. H. Hendrikse, A. Poot, D. J. Vugts, E. Thunnissen, P. Morin, D. Lipovsek, D. J. Donnelly, S. J. Bonacorsi, L. M. Velasquez, T. D. de Gruijl, E. F. Smit, A. J. de Langen

    Published 2018-11-01
    Get full text
    Article

Search Tools: